Stage IB Non-Small Cell Lung Cancer: Impact of the Number of Lymph Nodes Examined on Survival

被引:4
|
作者
Ceron, Jose [1 ]
Penalver, Juan Carlos [1 ]
Jorda, Carlos [2 ]
Padilla, Jose [1 ]
机构
[1] Hosp Univ La Fe, Serv Cirugia Toracica, Valencia, Spain
[2] Hosp Ribera, Serv Cirugia Toracica, Valencia, Spain
来源
ARCHIVOS DE BRONCONEUMOLOGIA | 2009年 / 45卷 / 02期
关键词
Bronchogenic carcinoma; Stage IB; Surgery; Survival; COMPLETE RESECTION; MEDIASTINAL LYMPHADENECTOMY; DISSECTION; RECURRENCE; PROGNOSIS; CLASSIFICATION; METASTASIS; MORBIDITY; MORTALITY; EXTENT;
D O I
10.1016/j.arbres.2008.05.003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction and Objectives: To determine the Causes of death in patients operated on for stage IB non-small cell lung cancer(NSCLC) and to assess the impact on survival of the number of lymph nodes removed. Patients and Method: We Studied 300 patients operated on for stage IB NSCLC. Only palpable or visible lymph nodes were excised. Kaplan-Meier survival estimates were calculated and the Survival Curves were Compared using the log-rank test. Results: The mean (SD) age of the patients was 62.9 (9.7) years: 280 were men, 20 were women. Pneumonectomy was performed in 84 patients, lobectomy in 186, double lobectomy in 23, and wginentectomy in 7. Squamous Cell carcinoma was the most common histologic type. The mean number of lymph nodes excised was 5.05 (5.01). At the time of the Study 201 patients (67%) had died, 63.2%. from causes related to the NSCLC, Overall 5-year survival for the patient series was 51.9% (median, 5.50 years: 95% confidence interval [CI], 4.14-6.87 years), though the 5-year survival rate was 61.87% after non NSCLC-related deaths were excluded (median, 11.05 years: 95% CI. 7.63-14.48 years). Tumor size and the number of lymph nodes examined significantly affected survival. In the multivariate analysis, these 2 variables Were also significantly correlated with the risk of death from NSCLC (P<.0001). with relative risks of 1.158 (95%, CI, 1.081-1.240) and 0.387 (95% CI, 0.254-0.591), respectively. Conclusion: Besides being affected by stage and tumor size, survival in patients operated on for stage IB NSCLC is significantly influenced by the total number of lymph nodes examined. Therefore, surgical treatment of such patients should include the examination of as many lymph nodes as possible. (C) 2007 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:87 / 91
页数:5
相关论文
共 50 条
  • [41] Prognostic roles of lymph node micrometastasis in non-small cell lung cancer
    Jeong, Jae Han
    Kim, Nae Yu
    Pyo, Jung-Soo
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (02) : 240 - 244
  • [42] Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion
    Xie, Jun
    Zhang, Xian
    Hu, Song
    Peng, Wan-Da
    Xu, Bin
    Li, Yan
    Zhang, Su-Juan
    Li, Qing
    Li, Chong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (09) : 2231 - 2239
  • [43] Proposal of a new nodal classification for operable non-small cell lung cancer based on the number of negative lymph nodes and the anatomical location of metastatic lymph nodes
    Liu, Hongfeng
    Yan, Tao
    Zhang, Tiehong
    Chen, Xiaowei
    Wang, Yadong
    Du, Jiajun
    MEDICINE, 2019, 98 (20)
  • [44] Assessment of non-lobe-specific lymph node metastasis in clinical stage IA non-small cell lung cancer
    Zhang, Zhirong
    Miao, Jinbai
    Chen, Qirui
    Fu, Yili
    Li, Hui
    Hu, Bin
    THORACIC CANCER, 2019, 10 (07) : 1597 - 1604
  • [45] Survival Impact of Stations of Pathological Lymph Nodes in N2 Non-small Cell Lung Cancer in a French Hospital
    Clement-Duchene, Christelle
    Luc, Amandine
    Casse, Jean-Matthieu
    Vignaud, Jean-Michel
    Lacomme, Stephanie
    Anne, Valentine
    Siat, Joelle
    Menard, Olivier
    Martinet, Yves
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (05) : 1262 - 1268
  • [46] Sarcoidal reactions in regional lymph nodes of patients with early stage non-small cell lung cancer predict improved disease-free survival: a pilot case-control study
    Steinfort, Daniel P.
    Tsui, Alpha
    Grieve, James
    Hibbs, Margaret L.
    Anderson, Gary P.
    Irving, Louis B.
    HUMAN PATHOLOGY, 2012, 43 (03) : 333 - 338
  • [47] Treatment Modality for Stage IB Peripheral Non-Small Cell Lung Cancer With Visceral Pleural Invasion and ≤3 cm in Size
    Huang, Weijia
    Deng, Han-Yu
    Lin, Ming-Ying
    Xu, Kai
    Zhang, Yu-Xiao
    Yuan, Chi
    Zhou, Qinghua
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] No prognostic impact of staging bone scan in patients with stage IA non-small cell lung cancer
    Zheng, Xia
    Li, Chunxia
    Ai, Jing
    Dong, Guili
    Long, Man
    Li, Mingyi
    Qiu, Shilin
    Huang, Yanni
    Yang, Guangjun
    Zhang, Tao
    Li, Zhenhui
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (07) : 534 - 543
  • [49] Adjuvant Chemotherapy for Patients with Stage IB Non-Small Cell Lung Cancer
    Wang, Jia
    Yue, Yang
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S641 - S642
  • [50] The prognostic impact of tumor volume on stage I non-small cell lung cancer
    Su, Xiao-Dong
    Xie, Hao-Jun
    Liu, Qian-Wen
    Mo, Yun-Xian
    Long, Hao
    Rong, Tie-Hua
    LUNG CANCER, 2017, 104 : 91 - 97